Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06911073 · ClinicalTrials.gov registry record · NA

A Study to Evaluate a Postbiotic in Supporting Weight Loss and Metabolic Health

A NA study of Obesity and Overweight, sponsored by ResBiotic Nutrition.

Recruiting
Registry status
NA
Development phase
80
Enrollment target
1
Study location

NCT06911073: Recruiting NA study of Obesity and Overweight, sponsored by ResBiotic Nutrition.

NCT06911073 is a NA study of Obesity and Overweight that is actively recruiting participants, run by ResBiotic Nutrition. The registered enrollment target is 80 participants, below the 462-participant average among 27 other Obesity and Overweight trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06911073, a NA study of Obesity and Overweight, is actively recruiting participants, sponsored by ResBiotic Nutrition.

RECRUITING
Registry status
NA
Development phase
80 participants
Enrollment target
1
Study location

Study Summary

This study aims to evaluate the impact of a specific oral postbiotic supplement on metabolic health in overweight adults.

Primary Outcome

Change from baseline in weight (lb)

Conditions Studied

Interventions

  • DIETARY_SUPPLEMENT Placebo
  • DIETARY_SUPPLEMENT Postbiotic

Study Locations (1)

Alabama

  • Able Biolabs, LLC - Birmingham

Trial Details

FieldValue
Enrollment Target 80 participants
Start Date 2025-05-02
Est. Completion 2025-12
Phase NA
ResBiotic Nutrition

2 total trials

What NCT06911073 shows while recruiting

NCT06911073 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 462-participant average among 27 other Obesity and Overweight trials with a reported enrollment target (83% lower).

The record links to 1 condition, with Obesity and Overweight appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06911073 reports a single indexed study location in Alabama.

Frequently Asked Questions

What is clinical trial NCT06911073 about?

NCT06911073 is a clinical study titled "A Study to Evaluate a Postbiotic in Supporting Weight Loss and Metabolic Health". This study aims to evaluate the impact of a specific oral postbiotic supplement on metabolic health in overweight adults.

What is the current status of trial NCT06911073?

This trial is currently recruiting. It is a NA study. The enrollment target is 80 participants. The study started on 2025-05-02. Estimated completion is 2025-12.

What conditions does trial NCT06911073 study?

This clinical trial studies the following conditions: Obesity and Overweight.

What interventions are being tested in trial NCT06911073?

The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), Postbiotic (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT06911073?

This trial is sponsored by ResBiotic Nutrition, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06911073 being conducted?

This trial has 1 study location across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Obesity and Overweight

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06911073's enrollment target sits among peer trials

80 12th of 27 higher than 16 of 27 other Obesity and Overweight trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Obesity and Overweight trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01243931 · 80 participants · NA

    Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy

  • NCT01659203 · 80 participants · Phase 1

    Proton or Photon RT for Retroperitoneal Sarcomas

  • NCT01803451 · 80 participants · Early Phase 1

    Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass

  • NCT01964859 · 80 participants · Phase 2

    Feasibility Study for Fibroblast Autologous Skin Grafts

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06911073, the US trial registry maintained by the National Library of Medicine. NCT06911073 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.